Sight Sciences to Report Second Quarter 2022 Financial Results on August 11, 2022
Sight Sciences (Nasdaq: SGHT) will release its Q2 2022 financial results on August 11, 2022, after market close. A conference call discussing the results is scheduled for 1:30 p.m. PT / 4:30 p.m. ET. Investors are encouraged to register for the audio webcast and will have access to a replay via the investor relations website. The company specializes in eyecare technology, aiming to improve care for prevalent eye diseases with innovative, minimally invasive solutions.
- None.
- None.
MENLO PARK, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announced it will report financial results for the second quarter ended June 30, 2022, after the market close on Thursday, August 11, 2022. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the audio webcast should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A replay of the webcast will be available at https://investors.sightsciences.com, in the News & Events section.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by an eye care professional to address the leading cause of dry eye disease.
For more information, visit www.sightsciences.com.
OMNI® and TearCare® are registered trademarks of Sight Sciences.
© 2022 Sight Sciences. All rights reserved.
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
FAQ
When will Sight Sciences report its Q2 2022 financial results?
What time is the Sight Sciences Q2 2022 conference call?
How can I listen to the Sight Sciences Q2 conference call?
Where can I find the replay of the Sight Sciences Q2 conference call?
What is the focus of Sight Sciences?
